Fraunhofer Institute for Toxicology and Experimental Medicine

Fraunhofer ITEM: News

Press release / 29.6.2022

Project FibroPaths®

Therapeutic modulation of organ fibrosis in biochip format. 

Press release / 3.6.2022

Project RNAuto

Fraunhofer develops automated production technologies for mRNA-based drugs.

Press release / 17.2.2022

New coronavirus vaccine

Researchers of the Hannover Medical School and of Fraunhofer ITEM want to test the efficacy of an inhaled vaccine.

News / 14.3.2022

Anti-fibrotic substances

New publication: Natural product-based compound screening identifies highly efficient anti-fibrotic substances.


Press release / 22.4.2022

RNA drug for treating cardiac fibrosis

EU is funding a research project on the therapy of cardiac fibrosis with around 2.5 million euros.


Press release / 1.3.2022

Checking the immune response in the lungs

Chip-based cell analysis by chip cytometry.


News / 15.2.2022

Inhaling microplastics – how dangerous is that?

Fraunhofer ITEM is investigating the inhalation toxicity of microplastics in a CEFIC-funded project.

Press release / 28.1.2022

EMA-funded project on nitrosamines

A joint research project led by Fraunhofer ITEM will shed light on the mutagenicity of N-nitrosamines.

Our research and development expertise

For more than four decades, we have been developing solutions for human health


Cardiopulmonary research

Through the establishment of a Division of Cardiovascular Research in 2021, the long-standing expertise in lung research is experiencing a synergetic further development of high clinical relevance. 

Medical and Pharmaceutical Engineering

Next to innovative inhalation technologies, our focus is on developing novel technologies for administration of therapeutic aerosols by means of smart drug/device combination products.


Malignant disease research

The Fraunhofer ITEM Division of Personalized Tumor Therapy in Regensburg is aimed at understanding a patient’s individual condition, establishing appropriate diagnostics and optimizing therapies.

Bioinformatics and AI

Our researchers develop methods for preparation, analysis and visualization of biomedical data, as well as data models and data analysis pipelines. The focus is on the mapping of cellular and regulatory processes and their translation into applications.



Based on the next generation risk assessment concept, Fraunhofer ITEM develops new assessment strategies to provide predictive models for assessing the safety of compounds, active pharmaceutical ingredients and drugs.


Immunology and infection research

The development, formulation and mode of delivery of anti-infective agents, for example for inhaled administration as drug aerosols, are research topics of current interest at the institute.

Our services


Chemical Safety and Assessment


Translational Biomedical Engineering


Personalized Tumor Therapy


Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0



20th Fraunhofer Seminar "Models of Lung Disease" and satellite workshop "Alternatives to Animal Testing"

The 20th Fraunhofer Seminar "Models of Lung Disease" will be held in Hannover, Germany, on June 23 and 24, 2022, with a thematic focus on lung infection. An additional satellite workshop on June 22, dedicated to alternatives to animal testing, can be booked separately or in combination with the main event. Online registration is open.
Read more


Fraunhofer CIMD Summer School 2022

The Fraunhofer Cluster of Excellence Immune-Mediated Diseases CIMD aims to facilitate and simplify education along the 4Ds (Drugs, Diagnostics, Data, Devices) by supporting young scientists. Cooperation between different disciplines is to be encouraged - a prerequisite for the implementation of 4Ds. In addition to various workshops along the 4Ds, the cluster is planning a summer school in Berlin, which is aimed at doctoral students and young postdocs (max. 2 years after doctorate) in the field of immune-mediated diseases.
Read more


SETAC Europe

At the SETAC Europe Annual Meeting in Copenhagen (Denmark) from May 15 to 19, 2022, Fraunhofer ITEM scientists will give insights into recent research work in oral and poster presentations.
Read more



In the past two years, the AACR Annual Meeting could take place in virtual formats only. This year’s meeting will now finally bring together international participants on-site in New Orleans (USA) and additionally on a virtual platform, given that this is the most important annual meeting in the field of cancer research worldwide.
Read more

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 75 institutes and research institutions of the Fraunhofer-Gesellschaft, the world’s leading applied research organization. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on cardiopulmonary research, our R&D portfolio includes three business areas: Drug Development, Chemical Safety and Translational Biomedical Engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of 394 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.


More information about Fraunhofer ITEM